The UK stock market has recently faced challenges, with the FTSE 100 and FTSE 250 indices experiencing declines amid weak trade data from China, which continues to impact global economic sentiment. In such an environment, identifying undervalued stocks can be particularly appealing as investors seek opportunities that may offer potential value despite broader market pressures.
Top 10 Undervalued Stocks Based On Cash Flows In The United Kingdom
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Yü Group (AIM:YU.) | £17.80 | £33.67 | 47.1% |
| Playtech (LSE:PTEC) | £3.77 | £7.29 | 48.3% |
| On the Beach Group (LSE:OTB) | £1.888 | £3.65 | 48.3% |
| Next 15 Group (AIM:NFG) | £3.045 | £5.75 | 47.1% |
| Eurocell (LSE:ECEL) | £1.175 | £2.21 | 46.9% |
| Entain (LSE:ENT) | £5.486 | £10.50 | 47.7% |
| Diaceutics (AIM:DXRX) | £1.445 | £2.89 | 50% |
| Convatec Group (LSE:CTEC) | £2.294 | £4.52 | 49.2% |
| Coats Group (LSE:COA) | £0.8165 | £1.62 | 49.7% |
| AstraZeneca (LSE:AZN) | £117.40 | £223.55 | 47.5% |
Here's a peek at a few of the choices from the screener.
Polar Capital Holdings (AIM:POLR)
Overview: Polar Capital Holdings plc is a publicly owned investment manager with a market cap of £785.11 million.
Operations: The company's revenue primarily comes from its Investment Management Business, generating £263.60 million.
Estimated Discount To Fair Value: 43%
Polar Capital Holdings appears undervalued based on cash flows, trading at £8.29 against a future cash flow value of £14.55. Its earnings grew by 66.2% last year and are expected to grow significantly at 21.76% annually, outpacing the UK market average of 11.9%. Despite slower revenue growth forecasts at 12% annually, it remains above the UK market's 4.3%. The company also maintains a reliable dividend yield of 5.55%.
- In light of our recent growth report, it seems possible that Polar Capital Holdings' financial performance will exceed current levels.
- Navigate through the intricacies of Polar Capital Holdings with our comprehensive financial health report here.
Convatec Group (LSE:CTEC)
Overview: Convatec Group PLC develops, manufactures, and sells medical products, services, and technologies for managing chronic conditions across Europe, North America, and internationally with a market cap of £4.48 billion.
Operations: The company's revenue segments include Advanced Wound Care ($640 million), Ostomy Care ($561 million), Continence & Critical Care ($462 million), and Infusion Devices ($332 million).
Estimated Discount To Fair Value: 49.2%
Convatec Group, trading at £2.29, is significantly undervalued based on cash flow estimates of £4.52. The company's earnings are projected to grow substantially at 24.9% annually, surpassing the UK market's 11.9%. Despite a high debt level and reduced net income of US$54 million in H1 2026 compared to US$105 million a year ago, Convatec's strategic initiatives and advanced wound care innovations position it for future growth and efficiency improvements.
- Our comprehensive growth report raises the possibility that Convatec Group is poised for substantial financial growth.
- Unlock comprehensive insights into our analysis of Convatec Group stock in this financial health report.
Informa (LSE:INF)
Overview: Informa plc is an international company that organizes events, provides digital services, and conducts academic research across the UK, Continental Europe, North America, China, and other global markets with a market cap of £11.39 billion.
Operations: The company's revenue is primarily derived from three segments: Live B2B Events (£3.06 billion), Taylor & Francis (£650.60 million), and Informa TechTarget (£361.40 million).
Estimated Discount To Fair Value: 13%
Informa, trading at £9.08, is slightly undervalued with cash flow estimates at £10.43 and trades 13% below fair value. Earnings grew by a large amount over the past year, with forecasts of significant annual profit growth (21.2%) surpassing the UK market's 11.9%. Despite high debt levels and low dividend coverage, recent buybacks totaling £214.2 million and an increased buyback plan indicate strong capital management efforts amidst modest revenue growth expectations (6.6%).
- The analysis detailed in our Informa growth report hints at robust future financial performance.
- Get an in-depth perspective on Informa's balance sheet by reading our health report here.
Seize The Opportunity
- Embark on your investment journey to our 43 Undervalued UK Stocks Based On Cash Flows selection here.
- Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
- Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.
Ready For A Different Approach?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com